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Zusammenfassung 
Patienten mit komplizierte Leberzirrhose leiden häufig an spontaner bakterieller 
Peritonitis (SBP). Die Aktivierung der Kupffer-Zelle (KC) durch Toll-like-Rezeptoren 
(TLRs) und die endotheliale sinusoidale Dysfunktion sind wichtige Mechanismen 
für die portale Hypertonie und das Fortschreiten der SBP. Thromboxan A2 (TXA2, 
das stabile Abbauprodukt ist TXB2) wurde bei der KC-Aktivierung als wichtiger 
Vasokonstriktor identifiziert. 
Die Pathophysiologie der KC-Aktivierung und die Funktion von TXA2 zur Erhöhung 
des Portalperfusionsdrucks nach Anwendung der TLR-Agonisten sind schon gut 
untersucht worden. Unklar ist jedoch welche TLRs auf KCs für die TXA2-Sekretion 
verantwortlich sind. In diesem Experiment wurden aus humanen (HKCs), THP-1-
Makrophagen (TMCs) und primären nichtparenchymalen Mauszellen [KCs, 
sinusoidale Endothelzellen (SECs) und hepatische Sternenzellen (HSCs)] isolierte 
primäre KCs untersucht. Zellen wurden durch mikrobielle Extrakte stimuliert, die 
aus kultivierten Isolaten von SBP-Patienten stammten. Mit speziellen TLR-
Agonisten und -Antagonisten wollten wir die Funktion von TLRs in nicht-
parenchymalen Leberzellen untersuchen. 
Unsere Daten zeigten, dass TLR-Agonisten nur TXB2 in Maus-KCs erhöhten, nicht 
jedoch in SECs oder HSCs. TLR-1, -2 und -4 spielten eine wichtige Rolle bei der 
TXB2-Sekretion in KCs nach bakterieller Stimulation. TLR-2 erkannte alle Arten von 
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mikrobiellen Isolaten. Vorbehandlung mit TLR-1, -2 oder -4-Antagonist könnte den 
TXB2-Anstieg durch gramnegative bakterielle Isolate (Klebsiella pneumoniae, 
Escherichia coli und Enterobacter cloacae) reduzieren. TLR-1 und -2-Antagonisten 
wirkten sich auch auf grampositive Bakterienisolate aus (Enterococcus faecium, 
Streptococcus pneumoniae und Staphylococcus aureus). Die Kombination von 
TLR-1, -2 und -4-Antagonisten erzielte eine bessere Wirkung als jedes einzelne 
Medikament. 
Nach unseren Erfahrungen sind dies die ersten Versuche zur Behandlung humaner 
primärer KCs mit verschiedenen klinisch relevanten humanen mikrobiellen Isolaten. 
TLR-1, -2 und -4 spielen eine wichtige Rolle bei der bakterieninduzierten TXB2-
Sekretion in HKC. TLR-2 spielt wahrscheinlich eine zentrale Rolle, da es sich auf 
alle bakteriellen Produkte auswirkt. Daher könnte TLR-2 in der Zukunft ein 
potenzieller Marker und ein attraktives Ziel für die Behandlung von Patienten mit 
SBP sein. 
 
 
 
 
 
 
LMU doctoral thesis                                                   Jiang Zhang  
9 
 
Abstract 
Background： 
Spontaneous bacterial peritonitis (SBP) is a bacterial infection that often occurs in 
patients with cirrhosis and can be fatal. Sinusoidal endothelial cells (SECs), Kupffer 
cells (KCs), and hepatic stellate cells (HSC) are major components of liver non-
parenchymal cells. They play an important role in combating pathogenic bacteria, 
usually the earliest cells that come into contact with antigens. Thromboxane A2 
(TXA2) was proved to be the critical vasoconstrictor secreted by activated KCs. 
Objection： 
We aimed to investigate the role of toll-like receptors (TLRs) in bacterial-induced 
TXA2 increase in liver nonparenchymal cells and to identify the most potent 
antagonists as potential therapeutic options in the future. 
Method： 
Primary nonparenchymal liver cells (including KCs, SECs, and HSCs) were isolated 
from mice, THP-1 macrophages (TMCs) differentiated by phorbol myristate acetate 
treatment and primary human KCs (HKCs) were investigated. Cells were 
characterized by immunostaining with special antibodies. Microbial isolates derived 
from patients with SBP and the special TLR-1 to -9 agonists were used to treat the 
related cells. TXB2, the stable degradation of TXA2, was measured in supernatants 
before and after stimulation. The special TLR-1/-2/-4 antagonists were additionally 
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added in some experiments 1 h before stimulation. 
Result： 
TLR agonists only increased TXB2 in mouse KCs (MKCs) but not in SECs or HSCs. 
TLR-1, -2 and -4 rather than other agonists caused TXB2 increase in HKCs and 
MKCs, TLR-1 and -2 agonists also worked on TMCs. Pretreatment with TLR-1, -2 
or -4 antagonist in HKCs significantly reduced the TXB2 increase caused by Gram-
negative bacteria. TLR-1 and -2 antagonist also had effects on Gram-positive 
bacteria. Only Mab-mTLR2 worked on Candida albicans-induced TXB2 increase. 
Combination of TLR-1, -2 and -4 antagonists achieved a better effect.  
Conclusion： 
This is the first study to investigate the effect of human microbial isolates on the 
vasoconstrictor TXA2 after stimulation and activation of human KCs. TLR-1, -2 and 
-4 play an important role in bacterial-induced TXA2 secretion, the TLR-2 antagonist 
showed the most effective reduction in bacterial-induced TXA2 secretion. Therefore, 
TLR-2 might be a potential marker and an attractive target for the treatment of 
infections and liver cirrhosis. 
 
Key words: toll-like receptor, spontaneous bacterial peritonitis, thromboxane A2, 
Kupffer cell, nonparenchymal liver cells.  
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Abbreviations 
Abbreviations Full name 
ACLF  acute-on-chronic liver failure 
BSA Bovine serum albumin 
C. albicans Candida albicans 
Cys-LT cysteinyl leukotrienes 
DC dendritic cells 
E. coli Escherichia coli 
E. cloacae Enterobacter cloacae 
E. faecium Enterococcus faecium 
ELISA The enzyme-linked immunosorbent assay 
FCS fetal calf serum 
FcyR Fc receptor 
FSL-1 Pam2CGDPKHPKSF 
GBSS Gey’s Balanced Salt Solution 
Gram (+) Gram-positive 
Gram (-) Gram-negative 
HKC human primary Kupffer cell 
HKLM heat-killed preparation of Listeria 
HSC hepatic stellate cells 
IR ischemia/reperfusion 
KC Kupffer cell 
K. pneumoniae Klebsiella pneumoniae 
LPS-EK Lipopolysaccharide E. coli K12 
LTC4 leukotrienes C4 
Mab-mTLR2 Monoclonal antibody to mouse TLR2 
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MKC mouse primary Kupffer cell 
NPC mouse primary Kupffer cell 
ODN CpG oligonucleotides 
Pam3CSK4 Pam3CysSerLys4 
PAMP pathogen-associated molecular pattern 
PBS phosphate-buffered saline 
PMA phorbol myristate acetate 
PFA Paraformaldehyde 
Poly(I:C) Polyinosinic-polycytidylic acid 
Poly(I:C)HMW Polyinosinic-polycytidylic acid (high molecular weight) 
Poly(I:C)LMW Polyinosinic-polycytidylic acid (low molecular weight) 
ssRNA single-stranded ribonucleic acid oligonucleotide 
SBP spontaneous bacterial peritonitis 
SD standard deviation 
SEC sinusoidal endothelial cell 
SFP spontaneous fungal peritonitis 
S. pneumoniae Streptococcus pneumoniae 
S. aureus Staphylococcus aureus 
ST-FLA S. typhimurium Flagellin 
TMC THP-1 macrophages 
TLR toll-like receptor 
TX Thromboxane 
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1. Introduction 
1.1 Role of infections in acute-on-chronic liver failure 
Cirrhosis, the end stage of many kinds of chronic liver disease, is characterized by 
the presence of certain anatomic abnormalities and fibrosis of hepatic parenchymal 
architecture [1, 2]. The clinical manifestations are similar and dominated by 
consequences of diminished hepatic reserve and portal hypertension, regardless 
of origin (alcoholic liver disease, autoimmune hepatitis, hepatitis virus especially 
hepatitis B and metabolic disorders) [3-6]. Esophageal varices, ascites and 
splenomegaly with malfunction of platelets are common complications of liver 
cirrhosis [5, 6].  
Patients with liver disease especially with cirrhosis often suffer from spontaneous 
bacterial peritonitis (SBP), a common and frequently fatal bacterial infection [7-10]. 
This is one of the most common and important complications of decompensated 
cirrhosis and is closely related to the patient's prognosis. Once SBP develops, the 
patient's mortality rate is greatly increased [7, 10, 11]. Therefore, the patient should 
be evaluated for liver transplantation once recovered from the first episode of SBP. 
The awareness and identification of early diagnosis and effective antibiotic strategy 
has reduced the mortality associated with first episode of SBP [7, 12].  
However, the selection of resistant organisms leads to changes in the antibacterial 
spectrum and the occurrence of certain diseases (such as candida esophagitis) are 
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non-negligible side effects in antibiotic treatment. The increasing prevalence of 
antibiotic-resistant bacteria, causing several hundred thousand deaths yearly, is 
recognized as a major global threat and one of the greatest therapeutic challenges 
[7, 12, 13]. Misuse and overuse of antibiotics are considered to be the major driver 
for the progress of antibiotic resistance. As a result, alternative therapies of 
antibiotics are now being seeked [7, 9, 10, 12].  
Gram (-) aerobic organisms such as Escherichia coli and Klebsiella pneumoniae 
are the most common cause of SBP patients, other common organisms include 
Enterobacter cloacae and Staphylococcus aureus [14, 15]. Candida albicans is 
reported as the most common pathogen of spontaneous fungal peritonitis [16, 17]. 
SBP is also the most common infection associated with acute-on-chronic liver 
failure (ACLF), which is characterized by a high morbidity and mortality due to 
systemic inflammatory response syndrome and multiple-organ dysfunction [18, 19]. 
ACLF is defined as the association of acute liver injury with established chronic liver 
disease leading to severe injury and can quickly lead to liver decompensation [20-
22]. Alcohol and hepatitis viruses are the most important causes of disease in 
Europe and Asia respectively [22, 23]. Bacterial translocation and sepsis play 
important roles in the process of cirrhosis and can cause sudden decompensation 
[23-25]. (Fig.1-1) 
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Fig.1-1 Role of infections in acute-on-chronic liver failure 
1.2 Role of nonparenchymal liver cells and toll-like receptors 
Nonparenchymal liver cells, mainly include hepatic stellate cells (HSCs), sinusoidal 
endothelial cells (SECs) and Kupffer cells (KCs), are the Important functional cells 
to meet bacteria (Fig.1-2) [26]. KCs are hepatic-resident macrophages that play a 
central role in the liver's inflammatory immune response. They are mainly involved 
in the recognition, presentation and phagocytosis of antigens.They can coordinate 
and regulate other nonparenchymal cells (NPCs) by secreting various cytokines. 
Shunting of blood away from KCs also allow a transient bacteremia to become more 
prolonged [14, 27]. KCs also express TLR-2, TLR-3, and TLR-9 and respond to 
their ligands [28-30]. KCs participate in immune activation and immunosuppression, 
both proinflammatory and anti-inflammatory cytokines such as interleukin (IL)-1b, 
IL-10 and tumor necrosis factor a (TNFa) can be secreted by KCs [29, 31-33]. 
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Fig.1-2 Architecture of the Liver 
Toll-like receptors (TLRs) play vital roles in innate immune defenses against diverse 
set of pathogen-associated molecular patterns (PAMPs) by KCs. Examples of 
PAMPs include Gram (-) and Gram (+) bacterial components, fungi, and protozoa 
[34, 35]. The liver is continuously stimulated by antigens from the gastrointestinal 
tract and transmitted through the portal vein. With the arrival of foreign antigens in 
the liver, TLRs activate and maintain immune activation resulting in immediate 
release of cytokines and antimicrobial peptides by immune cells. In addition, TLR 
signaling also plays a key role in regulating immune tolerance [36-38]. Special 
agonists of TLR-1 to -9 have been widely used in different kinds of cell lines and 
primary macrophages [39]. TLR-2 can form complexes with other TLRs (TLR-6 or 
TLR-1…). TLR-3, -7, -8 and -9 are intracellular TLR sensors and mainly respond to 
nucleic acids such as double and single-stranded RNA from virus [40]. (Fig.1-3) 
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TLR-2 signaling activates the inflammasome primarily in KCs, but not in HSCs or 
hepatocytes [41, 42]. Expression of TLR-1, -2 and -4 also found as potential 
indicators for a variety of diseases. Expression of soluble TLR-2 were higher in 
patients with psoriasis [43]. TLR-2 and -4 expression in monocytes was found to be 
significantly overexpressed in patients with tuberculosis [44], systemic lupus 
erythematosus [45] and myelodysplastic syndromes [46]. TLR-2 and -4 were 
reported to be independently associated to poor outcome of patients with ischemia 
stroke and intracerebral hemorrhage [47, 48], higher methylation of TLR-2 may also 
confer susceptibility to adverse cardiac autonomic effects [49]. 
 
 
Fig.1-3 The role of TLRs 
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1.3 Development and reversibility of liver cirrhosis 
Liver cirrhosis, the fourth cause of death due to non-communicable diseases, is 
characterized by patterns of evolution and complex pathophysiological changes. 
Traditionally, cirrhosis is a progressive and irreversible disease, and wound healing 
is an important starting event [50]. A marked reduction in mortality gained over the 
last decades because of the improved management and new knowledge on the 
mechanism, pathophysiology and therapy of cirrhosis [51, 52]. More and more 
researchers now approve that the description of liver cirrhosis as a static disease 
has now become inappropriate. At present, the process of cirrhosis is not only 
considered to be the result of physical effects of portal hypertension (such as scar 
and liver formation of cirrhosis), but also related to the production of a dynamic 
compound, namely the production of intrahepatic vasoconstrictors [50, 51, 53]. 
In this new way of understanding, pathological changes of vessels of the liver 
aggregating portal hypertension play vital roles on cirrhosis, resulting in a series of 
complications. Derangement of vascular networks, vascular thrombosis, formation 
of intrahepatic shunts, capillarization of sinusoids and perisinusoidal fibrosis are 
essential and important bases of the vascular pathological changes in cirrhosis [50, 
51, 53]. One of the key target events for reversing fibrosis is the behavior of rapid 
closure that often occurs during chronic wound healing [50, 53]. Progressive 
reduction of necrotic inflammation is an important feature of the wound healing 
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process. Macrophages have been widely demonstrated to play an extremely 
important role in the study of fibrosis, not only in the progression of fibrosis but also 
in the regression of fibrosis [50, 54]. Soluble factors and cytokines such as IL-6. 
TNF-α, IL-8 and MCP-1 are important regulatory pathways that regulate 
macrophage’s function, activity, and connection with other fibrosis-associated cells 
(such as HSC, SEC) [55]. Molecules associated with the development of fibrosis 
are widely expressed in these cells and interact with portal vein fibroblasts, which 
are usually mediated by pro-inflammatory and chemotactic cytokines [56]. Changes 
in inflammatory factors caused by bacterial translocation affect the progression of 
cirrhosis [57-59]. (Fig. 1-4)  
 
Fig.1-4 Mechanisms of liver cirrhosis  
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1.4 The pathophysiology of KC activation and function of TXA2 
KC activation by TLR agonists and endothelial sinusoidal dysfunction were 
important mechanisms for portal hypertension and progression of ACLF [14]. 
Thromboxane (TX) A2 has been identified as an important vasoconstrictor in this 
process and plays important roles on vascular constriction, platelet activation and 
aggregation [60, 61]. TXA2 exerts its specific biological activity by binding to 
thromboxane prostanoid (TP) receptor and activating the associated downstream 
proteins. During acute inflammation, hepatic microcirculatory dysfunction mediated 
by TNF-α can be regulated by TXA2/TP receptor signaling pathway through 
enhancement of proinflammatory mediators [61-63].  
TXA2 and can also be induced by non-alcoholic fatty liver disease and activated by 
the interaction with blood components. In patients, increased TXA2 synthesis was 
linked to infections, renal diseases, acute myocardial ischemia and heart failure [64, 
65]. Aspirin has been proved to abolish TXA2 generation and block platelet 
activation by responses [66, 67]. Significant changes in microcirculation effects 
occur when TXA2 synthesis is inhibited [68]. Previous publications also reported 
TXA2 inhibitors attenuated liver injury induced by ischemia/reperfusion, alcoholic 
liver injury, inflammation, fibrotic changes and liver injury induced by 
acetaminophen overdose elements [62, 69].  
The pathophysiology of KC activation and function of TXA2 to increase portal 
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perfusion pressure following TLR agonists have been well investigated in previous 
publications [14, 27, 32, 70]. In isolated rat liver perfusion models, TXA2 and 
cysteinyl leukotrienes (Cys-LT) are proved to be important players in the portal 
pressure increase. We have demonstrated the important role for TXA2 during the 
portal perfusion pressure increase after TLR activation: activated KCs release TXA2 
and then stimulate HSCs to produce subsequent effects, ultimately leading to 
contractile cell contraction and increased portal perfusion pressure. Intrahepatic 
vascular hyperreactivity and intrahepatic resistance are also important elements 
aggravating portal hypertension. (Fig. 1-5)  
 
 
Fig.1-5 The pathophysiology of KC activation and function of TXA2 
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1.5 Aims of the study 
However, which TLRs on KCs are responsible for the TXA2 secretion by bacterial 
infections are still unclear. In this experiment, primary nonparenchymal liver cells 
(including KCs, SECs, and HSCs) were isolated from mice, THP-1 macrophages 
(TMCs) differentiated by phorbol myristate acetate (PMA) treatment and primary 
human KCs (HKCs) were investigated. Cells were stimulated by microbial extracts 
derived from cultured isolates of SBP patients. Together with special TLR agonists 
and antagonists, we aimed to investigate the role of toll-like receptors (TLRs) in 
bacterial-induced TXA2 increase in liver nonparenchymal cells and to identify the 
most potent antagonists as potential therapeutic options in the future.  
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2. Materials and methods 
2.1 Animal and human tissue studies 
All mice were adapted to the new environment for 1 week before experiment and 
were ethically treated according to rules and regulations. The Biobank of the 
Department of General, Visceral and Transplantation Surgery, Ludwig-Maximilians 
University provided human liver tissue under the administration of the Human 
Tissue and Cell Research (HTCR) Foundation.  
2.2 Isolation of primary nonparenchymal liver cells 
2.2.1 Separation of KCs and HSCs 
2.2.1.1 Preparations 
Material sterilization: 4 * empty beakers; 2 * beaker covered with 80 μm and 60 μm 
nylon mesh (Sigma, St. Louis, USA); 2 * Spoon; 2 * stirred fish; 2* aluminum foil; 
pipette tip kits: 1 * box for 1000 μl; 1 * box for 100 μl; 1 * box for 10 μl and several 
EP tubes. 
Fresh Nycodenz solution: Nycodenz solution (0.75% NaCl with Tris –HCl, KCl and 
0.3 mM CaNa2 EDTA) with stirring is heated to 50 °C, then slowly add Nycodenz 
powder (Axxis Shield, Rodelokka, Norway). After the Nycodenz powder is 
completely dissolved, the solution is naturally cooled to room temperature (RT). 
0.75% NaCl solution and 60 ml Gey’s Balanced Salt Solution (GBSS, Sigma, St. 
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Louis, USA) are finally added to achieve the required concentraction. 
Pronase solution: 300 mg pronase (Sigma, St. Louis, USA) is dissolved into 20 ml 
GBSS and Closed with aluminum foil (light-shielded) and rolls until they are ready 
for use. 
2.2.1.2 Obtain liver tissues from mice 
Remove the animal from the cage and fix in the left hand. Intraperitoneal 
administration of 150 mg/kg Ketamine (Ketamidor, Chanelle, Galway, Ireland) + 10 
mg/kg Xylazine (Xylavet, CP-Pharma Handelsges, Burgdorf, Germany) for 
anesthesia and return to the cage. After falling asleep, verify the depth of anesthesia 
based on its reflex. If necessary, reapplicate of Ketamine and Xylazine. The 
abdominal wall was then opened, exposure to the liver, portal vein and inferior vena 
cava. Flanking of the portal vein and perfusion with heparin-diluted PAA (RPMI 1640 
from PAA, heparin 1,000 IU to 50 ml). The inferior vena cava is immediately cut off, 
causing the animal to bleed and die, and then remove the liver. 
2.2.1.3 Liver slicing and digestion 
Add the liver tissues from human or mouse without medium to a petri dish. Using 2 
sterile scalpels, first superficially, then deeply cut. After the tissue is completely cut 
into 5–10 mm thick slices, the mass is added to a sterile beaker with a spoon and 
washed with sterile phosphate-buffered saline (PBS, Sigma, USA). Change PBS 
with 130 ml GBSS, DNase (Roche, Mannheim, Germany), the sterile pronase 
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(filtered with Minisart filter 0.2 μm pore size, Sigma, USA) and a sterile stirred fish 
in the beaker. Cover the beaker with sterile aluminum foil and pack it with an 
unsterile aluminum foil in a light-proof manner. Then the liver mass is incubated in 
the incubator (Incubator IF30, Memmert, Germany) at 37 °C for 20 min. 
2.2.1.4 Filtration and centrifugation with Nycodenz solution 
After 20 min of digestion, the solution is filtered through an 85 μm filter, which is 
stretched over a beaker. The rest tissues upon the filter are added into a 
Stomacher® 400 circular bags (Sigma, St. Louis, USA) with 100 ml GBSS + DNase. 
Close the Stormacher bag without bubbles and grind (Stomacher® 400 circulator, 
Seward, England). The solution from stomacher bag is then filtered through the 85 
μm and 65 µm filter sequentially.  
Distribute the solution under the 65 μm filter into approximately 6 * 50 ml falcon 
tubes. After distribution, centrifuge at 300 g for 10 min at 4 °C, with brake. Aspirate 
the supernatant, the pellet is resuspended with 30 ml GBSS in each tube. The 
Nycodenz solution is filtered in 6 * 50 ml Falcon tubes, 20 ml solution in each tube. 
The liver solutions are slowly added and layered on the sterile Nycodenz solutions 
(17.6% for KCs and 28.7% for HSCs). The mixtures are centrifuged at 600 g for 20 
min at RT without brake. 
Discard 20 ml of the upper layer, collect the interfaces in 2-3 orange tubes. The 
collections are centrifuged at 2000 g for 5 min with brake. The pellet is resuspended 
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in RPMI 1640 supplemented with penicillin (100 units/mL, Sigma, St. Louis, USA), 
and streptomycin (Sigma, St. Louis, USA) together with L-glutamine, fetal calf 
serum (FCS, PAA, Cölbe, Germany). 
2.2.1.5 Cell counting and plating 
After cell counting, KCs or HSCs are seeded in plates and cultured at 37 °C in 5% 
CO2 (Incubator HeRA CELL 240, Heraeus, Germany). Before stimulation, the 
medium is changed by RPMI 1640 without FCS for 24 h. 
2.2.2 Separation of SECs 
2.2.2.1 Preparation and liver tissue digestion are the same as KCs and HSCs. 
2.2.2.2 Magenetic labeling and separation 
Wash the pellet after centrifuge and then centrifuge again for 5 min at 300 g. Count 
and resuspend 1 ml of medium with 1×107 cells. Add 10μl Anti-SEC MicroBeads 
CD146 (Miltenyi Biotec, Germany) for immunolabeling. After incubation, seperate 
SECs with magnetically activated cell sorting system MACS (Miltenyi Biotec, 
Germany). Recount and then seed the SEC at the appropriate density and condition. 
2.3  Culture and differentiation of THP-1 cell line 
THP-1 monocytic cell (American Type Culture Collection, ATCC reference number 
TIB-202TM) was a kind gift from prof. Peter Nelson. Cells were cultured in complete 
RPMI 1640 medium including 10% FCS. THP-1 monocytes were differentiated to 
macrophages by 24 h stimulation with medium containing 20 ng/ml phorbol 
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myristate acetate (PMA, Sigma, St. Louis, USA). Adherent cells were incubated 
with fresh RPMI 1640 medium without PMA after washing with PBS [72, 73]. Before 
stimulation, the medium was changed by RPMI 1640 without FCS for 24 h. 
2.4  In vitro stimulation plan 
The following microbes were isolated from patients with SBP: Klebsiella 
pneumoniae (K. pneumoniae), Enterococcus faecium (E. faecium), Escherichia coli 
(E. coli), Staphylococcus aureus (S. aureus), Streptococcus pneumoniae (S. 
pneumoniae), Enterobacter cloacae (E. cloacae) and Candida albicans (C. albicans) 
were cultured on special media (Becton Dickinson, Heidelberg, Germany) at 37°C 
under aeration. After growth, the isolates were gently taken off the media and 
resuspended in PBS. The isolates were washed three times to remove any residual 
media attaching to the isolates. Subsequently, the microbial pellet was collected by 
centrifugation (5000rpm, 4°C, 10min) and resuspended in a small volume of PBS 
and subsequently heat inactivated (98°C, 20min). The heat inactivated solution was 
vortex mixed and checked for sterility by plating it twice on Columbia 5% sheep 
blood media and inoculation in liquid broth. All extracts were found to be sterile and 
were measured for protein content using the Bradford technique. Extracts were 
diluted to achieve standardized protein concentration.  
Preparation of human and mouse TLR agonist stock solutions (Invivogen, USA) 
was according to the instructions of the drugs (Table. 2-1). Administered 
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concentrations of TLR agonists were as following: TLR-1/2, Pam3CSK4, 0.1µg/ml; 
TLR-2, HKLM, 108cells/ml; TLR-3, Poly(I:C)HMW, 10ng/ml; TLR-3, Poly(I:C)LMW, 
10ng/ml; TLR-4, LPS-EK, 10ng/ml; TLR-5, FLAST, 10ng/ml; TLR-6/2, FSL-1, 
1µg/ml; Imiquimod, 1µg/ml (TLR-7 for human); ssRNA40, 0,25µg/ml (TLR-8 for 
human and TLR-7 for mouse, mouse lack TLR-8); ODN2006, 5µM (TLR-9 for 
human) and ODN1826, 5µM (TLR-9 for mouse).  
In some experiments, the special TLR-1/-2/-4 antagonists (CU-CPT22, Merck, 
Germany; Mab-mTLR2, Invivogen, USA; TAK242, Merck, Germany) were 
additionally added 1 h before stimulation. Supernatants were stored at -80 °C 
before use.   
 
Product Application 
Stock solution 
concentration 
Volume of solvant 
Pam3CSK4 Human, Mouse 100 ng/ml 100 µl H2O 
HKLM Human, Mouse 1010 cells/ml 100 µl H2O 
Poly(I:C)HMW Human, Mouse 1 mg/ml 500 µl H2O 
Poly(I:C)LMW Human, Mouse 1 mg/ml 500 µl H2O 
LPS-EK Human, Mouse 100 µg/ml 1 ml H2O 
FLAST Human, Mouse 100 µg/ml 100 µl H2O 
FSL-1 Human, Mouse 100 µg/ml 100 µl H2O 
Imiquimod Human 100 µg/ml 250 µl H2O 
ssRNA40 Human, Mouse 100 µg/ml 250 µl H2O 
ODN2006 Human 500 µM 26 µl H2O 
ODN1826 Mouse 500 µM 31 µl H2O 
Table. 2-1 Preparation of TLR agonist stock solutions 
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2.5  ELISA measurement 
TXA2 secretion was quantified by the release into supernatants of cells. The 
procedures were based on the instructions and protocols in our publications before 
[27, 32]. TXB2 enzyme-linked immunosorbent assay (ELISA) kit (Cayman Chemical, 
USA) was used to measure the stable degradation product of TXA2.  
2.5.1 Sample and TXB2 standard preparation 
If necessary, dilute the sample to the appropriate concentration with ELISA buffer. 
Prepare the standard solution: Mix 100 µl of TXB2 ELISA standard and 900 µl 
UltraPure water (Cayman Chemical, USA) into a tube. Use 8 clean test tubes, 
marking number from S1 to S8. S1 is filled with 900 µl and the rest tubes are filled 
with 600 µl ELISA buffer each. Transfer 100 µl standard solution to S1 and mix 
thoroughly. Then mix 400 µl from S1 with the solution in S2. Repeat this processs 
until S8. (Fig. 2-1) 
 
Fig. 2-1 Preparation of TXB2 standard 
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2.5.2 Performing the assay 
A clean 96-well plate was used to design and seperate samples into different groups 
(Fig. 2-2). Add the regents of ELISIA buffer, standard solutions, samples, TXB2 
AChE Tracer and TXB2 ELISIA Antiserum into different kinds groups in the plate 
(Table. 2-2). After incubation overnight, empty the plate. Each well were filled with 
200 µl fresh Ellman’s Reagent after 5 times washing. Cover the plate with aluminum 
foil and develop. Develop the plate in 90-120 min with an orbital shaker (Orbital 
shaker SSL, Stuart, United Kingdom). Read plate at 405 nm wavelength light 
(Glomax Detection System, Promga, USA). 
 
 
Fig. 2-2 Design of sample plate 
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Well 
ELISA 
Buffer 
Standard/Sample Tracer Antiserum 
Blk - - - - 
TA - - 5 µl (deve.step) - 
NSB 100 µl - 50 µl - 
B0 50 µl - 50 µl 50 µl 
Standard/Sample - 50 µl 50 µl 50 µl 
Table. 2-2 Addition of reagents 
2.5.3 Calculation 
Calculate and make the standard curve with the analysis temple from Cayman, then 
determine the sample concentration for each well. 
2.6  Western Blot 
2.6.1 Extraction and preparation of protein samples 
Wash the cells with PBS on ice and then replace PBS with lysis buffer (1 ml 
containing 845µl RIPA-buffer (Sigma, St. Louis, USA), 40 µl cOmplete solution 
(cOmplete™ Protease Inhibitor Cocktail, Sigma, USA), 5µl Phenylmethylsulfonyl 
fluoride (PMSF, 200 mM, Sigma, USA), 5µl Sodium fluoride (NaF, 200 mM, Sigma, 
USA), 5µl Sodium orthovanadate (Na3VO4, Sigma, USA) and 100µl Triton-X-100 
(Sigma, USA). Scrape cells and collect the suspension. After vortex oscillation, 
centrifuge at 12,000 rpm for 20 min (Biofugo, Heraeus, Germany). Transfer the 
supernatant to a new tube. 
2.6.2 Protein concentration calculation and sample preparation 
Prepare the standard solutions with Bovine serum albumin (BSA, 1 mg/ml, Sigma, 
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USA) as following 
Standard density(μg/ml) BSA volume(μl) ddH2O volume(μl) 
0 0 200 
10 2 198 
100 20 180 
200 40 160 
400 80 120 
600 120 80 
800 160 40 
1000 200 0 
Fill the 96 well plates with 5 µl standard or sample in each well. Mix Bicinchoninic 
Acid (BCA) reagents A & B with the ratio 50:1, and then add 200 μl mixed regents 
in each well. After incubation, measure the absorbance at 562 nm wavelength light 
(Glomax Muti Detection System, Promga, USA). Add suitable volume 4X loading 
buffer (Sigma, USA).  
2.6.3 Running the gel 
Add samples and the marker (Sigma, USA) in the appropriate concentration of gel.  
Protein Size Gel pecentage 
4-40 kDa  20% 
12-45 kDa  15% 
10-70 kDa 12.5% 
15-100 kDa 10% 
25-100 kDa 8% 
Run the gel for proper time and voltage (Mini-PROTEAN® System, Bio-Rad, USA). 
2.6.4 Transferring the protein to the membrane 
Activate Polyvinylidene difluoride (PVDF) membrane with methanol and prepare 
the stack. Transfer for 60-90 min at 400 mA. 
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2.6.5 Antibody staining 
Incubate the membrane with primary antibody after blocking for 1 h: anti-TLR2 
antibody (1:1000, RabMab, England); anti-TLR1 antibody (1:1000, Arcis, Germany); 
ß-actin antibody (1:1000, Sigma, USA). Incubate with primary antibody overnight at 
4 °C. Wash the membrane in Tris buffered saline with Tween 20 (TBST, Sigma, 
USA). Incubate the membrane with the secondary antibody. Then, wash the 
membrane. 
2.6.6 Membrane development 
Prepare Working Solution (SuperSignal™ West Femto, Thermo Fisher, USA). Add 
Working Solution on membrane. Remove the solution after incubation and then 
expose the blot to the imaging system (CHEMOCAM Imager 3.2, INTAS Science 
imaging, Germany). 
2.7  Immunofluorescence and confocal microscopy 
Primary antibodies against CD163 (1:100; Acris, Germany), CD68 (1:100; Arcis, 
Germany), CD11b (1:100; Santa Cruz Biotechnology, USA), F4/80 (1:100; RabMab, 
England) were used to confirm the isolated human and mouse primary KCs and 
differentiated THP-1 macrophages as following steps.  
Culture the cells in the 8-well Culture Slides (Ibidi, Germany), about 1000 cells/well.  
Discard the medium, wash 3 times. Fix the cells with 4% paraformaldehyde (PFA) 
for 15 min. Add 10 mM Ethamlamine (Sigma, USA) for 5 min to remove remaining 
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PFA after washing with PBS. Wash again and add 0.01% Triton-X-100. Block with 
Albumin (1% BSA). Incubate with primary antibody overnight at 4 °C. The next day, 
incubate with secondary antibodies Alexa Fluor (Life Technologies GmbH, 
Darmstadt, Germany) for 1h in RT after washing with PBS. Wash again, 15min each. 
Add DAPI (10000x) 2min. Wash with PBS. Analyse cells (Zeiss LSM 510 META, 
Jena, Germany) 
2.8  Statistical analysis 
All samples were randomly distributed to different groups. Data were described as 
the mean ± standard deviation (SD). The Students t-test and One-way analysis of 
variance (ANOVA) were used when needed. Statistical significance was defined as 
A value of p<0.05; n denotes the number of samples used. SPSS and Graphpad 
were used for data analysis and figure drawing. 
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3. Results 
3.1 Immunofluorescence results of different macrophages 
Special antibodies were used to confirm the isolated primary KCs and differentiated 
THP-1 cells. Identification of macrophages such as KCs in tissue sections is usually 
stained by immunohistochemistry of CD68 or CD163 antibodies. The expression of 
CD68 in tissue macrophages is more extensive, while CD163 is more specific. In 
addition, CD163 is also commonly considered to be a M2 macrophages’ marker [74, 
75]. CD11b and F4/80 are specific markers for mature macrophages, of which 
F4/80 is mouse specific. Immunofluorescence with CD68, CD163 and CD11b 
positive confirmed the cells we isolated from human tissue were human KCs (Fig.3-
1). CD68, CD163 and F4/80 positive immunofluorescent results in mouse primary 
cells also confirmed these cells were mouse KCs (Fig.3-2).  
THP-1 cells, the most widely used monocytic cell lines to investigate macrophages, 
were suspension cells before PMA treatment. 24 h after PMA treatment, THP-1 cells 
became adherent cells with typical morphological characteristics. 
Immunofluorescent results with CD11b, CD68 positive and F4/80 negative in these 
cells also identified these THP-1 macrophages (TMCs) (Fig.3-3).  
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Fig.3-1 Immunofluorescence results of human KCs 
(Each picture represents from three separate results, 200x magnification) 
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Fig.3-2 Immunofluorescence results of mouse KCs 
(Each picture represents from three separate results, 200x magnification) 
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Fig.3-3 Immunofluorescence results of TMCs 
(Each picture represents from three separate results, 200x magnification) 
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3.2 Influences of microbial isolates on TXB2 secretion 
According to published articles [76, 77] and our pretest results, we designed the 
concentration gradient experiments with low, middle or high concentrations (the 
standardized protein concentration) to confirm the suitable stimulating doses for 
different kinds of microbial isolates. The middle concentration showed the most 
effective increase in TXB2 section on TMCs for all kinds of isolates (Fig. 3-4). The 
effects of 8µg/ml microbial isolates were also tested in primary KCs from mice and 
human. After 24 h stimulation, 7 kinds of microbial isolates all significantly increased 
TXB2 secretion in HKCs (Fig. 3-5) and MKCs (Fig. 3-6). Due to individualized 
differences in the source of tissue specimens, primary KCs of human and mouse 
were compared with standardized results (multiple increases in TXB2 levels before 
and after stimulation). 
Microbial 
isolates 
Human KCs  
(increased fold) 
Mouse KCs  
(increased fold) 
THP-1 macrophages  
(pg/ml) 
K. pneumonia 1.00±0.13 vs. 8.02±5.51 * 1.00±0.20 vs. 3.52±1.48 * 117±58 vs. 5049±3490 * 
E. coli 1.00±0.24 vs. 10.19±7.49 * 1.00±0.34 vs. 3.49±1.44 * 244±114 vs. 2435±1459 * 
E. cloacae 1.00±0.11 vs. 18.44±12.62 * 1.00±0.18 vs. 5.23±3.17 * 275±268 vs. 7619±2032 * 
E. faecium 1.00±0.45 vs. 5.71±1.83 * 1.00±0.29 vs. 4.14±3.01 * 104±68 vs. 4145±2613 * 
S. pneumonia 1.00±0.09 vs. 3.07±0.78 * 1.00±0.20 vs. 8.99±1.83 * 192±192 vs. 3278±2163 * 
S. aureus 1.00±0.15 vs. 8.65±2.19 * 1.00±0.29 vs. 10.77±1.19 * 257±291 vs. 4663±901 * 
C. albicans 1.00±0.15 vs. 2.46±1.41 * 1.00±0.39 vs. 8.00±2.87 * 180±94 vs. 4724±2640 * 
Table. 3-1 Influences of microbial isolates on TXB2 secretion 
Data are expressed as mean ± SD, *p < 0.05 comparing between values before 
and after stimulation, *p < 0.05, two-tailed t-test. 
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Fig.3-4 Concentration gradient experiments of microbial isolates 
Low (1 µg/ml), middle (8 µg/ml) and high (32 µg/ml) concentrations of different kinds 
of bacteria were used to stimulate differentiated THP-1 macrophages, the middle 
concentration seemed to be the most effective for all kinds of bacteria. Data are 
expressed as mean ± SD, two-tailed t-test, *p < 0.05 comparing between values 
before and after stimulation, n=4 in each group. 
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Fig.3-5 Microbial isolates increased TXB2 secretion in human KCs 
24 h stimulation with microbial isolates including A-Klebsiella pneumoniae, B-
Escherichia coli, C-Enterobacter cloacae, D-Enterococcus faecium, E-
Streptococcus pneumoniae, F-Staphylococcus aureus and G-Candida albicans 
significantly increased TXB2 secretion in human KCs. Data are expressed as mean 
± SD, two-tailed t-test, *p < 0.05 comparing between values before and after 
stimulation, n=6 in each group. 
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Fig.3-6 Microbial isolates increased TXB2 secretion in mouse KCs 
24 h stimulation with microbial isolates including A-Klebsiella pneumoniae, B-
Escherichia coli, C-Enterobacter cloacae, D-Enterococcus faecium, E-
Streptococcus pneumoniae, F-Staphylococcus aureus and G-Candida albicans 
significantly increased TXB2 secretion in mouse KCs. Data are expressed as mean 
± SD, two-tailed t-test, *p < 0.05 comparing between values before and after 
stimulation, n=6 in each group. 
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3.3 Influence of TLR-1 to -9 agonists in KCs and TMCs 
TLR-1 to -9 agonists (names and stimulating dosages were described above) were 
used to investigate the effective TLRs increasing TXB2 in KCs. 24 h stimulation with 
Pam3CSK4, HKLM or LPS significantly increased TXB2 secretion in HKCs (Fig. 3-
7). The same treatment with TLR-1/2, -2 and -4 agonists in MKCs also resulted in 
the increased TXB2 production (Fig. 3-8). Besides Pam3CSK4 and HKLM, 
Poly(I:C)-LMW and ODN2006 also induced significant TXB2 increase in TMCs (Fig. 
3-9). Interestingly, LPS had no significant effect on TMCs (Fig. 3-9). Details are 
shown in Table. 3-2. 
Comparing among the effects of TLR1-9 agonists on HKCs, MKCs and TMCs, TLR-
1, -2 and -4 were most possiblily related to the microbial-induced TXB2 increase in 
KCs. Western blot with anti-TLR-1 and anti-TLR-2 antibodies were then used to 
confirm the activated TLRs on TMCs following stimulation with different kinds of 
microbial isolates. TLR-1 and -2 expression on TMCs were elevated by all tested 
isolates, However, Gram (-) isolates (K. pneumonia, E. coli and E. cloacae) were 
more effective than Gram (+) isolates (E. faecium, S. pneumoniae and S. aureus) 
and C. albicans showed the least effect (Fig. 3-10). 
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Fig.3-7 TLR-1/2, -2 and -4 agonists increased TXB2 secretion in human KCs 
Among all TLR-1 to -9 agonists, only Pam3CSK4 (B-0.1 µg/ml, 24 h), HKLM (C-
10e8 cells/ml, 24 h) and LPS-EK (F-10ng/ml, 24 h) significantly increased TXB2 
secretion in human KCs. Data are expressed as mean ± SD, two-tailed t-test, *p < 
0.05 comparing between values before and after stimulation, n=6 in each group.  
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Fig.3-8 TLR-1/2, -2 and -4 agonists increased TXB2 secretion in mouse KCs 
Among all TLR-1 to -9 agonists, only Pam3CSK4 (B-0.1 µg/ml, 24 h), HKLM (C-
10e8 cells/ml, 24 h) and LPS-EK (F-10ng/ml, 24 h) significantly increased TXB2 
secretion in mouse KCs. Data are expressed as mean ± SD, two-tailed t-test, *p < 
0.05 comparing between values before and after stimulation, n=6 in each group.  
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Fig.3-9 TLR-1/2, -2, -3 and -9 agonists increased TXB2 secretion  
in THP-1 macrophages 
24 h stimulation with Pam3CSK4 (B-0.1 µg/ml), HKLM (C-10e8 cells/ml), Poly(I:C)-
LMW (E-10ng/ml) and ODN2006 (K-5µM) had significant effects in differentiated 
THP-1 macrophages. Data are expressed as mean ± SD, two-tailed t-test, *p < 0.05 
comparing between values before and after stimulation, n=6 in each group.  
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Fig.3-10 TLR-1 and -2 expression on TMCs following  
microbial isolates stimulation 
24 h stimulation with microbial isolates including K. pneumoniae, E. coli, E. cloacae, 
E. faecium, S. pneumoniae, S. aureus and C. albicans (8µg/ml each, 24h 
stimulation) increased TLR-1 and -2 on TMCs. Expression by Gram (-) isolates were 
more effective than Gram (+) isolates and C.albicans showed the least effect. 
TLR agonists 
Human KCs  
(increased fold) 
Mouse KCs  
(increased fold) 
THP-1 macrophages  
(pg/ml) 
Control 1.00±0.41 vs. 1.21±0.45 1.00±0.53 vs. 0.89±0.66 103±61 vs. 118±71 
Pam3CSK4 1.00±0.05 vs. 12.69±10.10 * 1.00±0.53 vs. 9.23±8.63 * 145±47 vs. 1082±975 * 
HKLM 1.00±0.39 vs. 16.41±14.43 * 1.00±0.54 vs. 5.10±1.95 * 123±41 vs. 1661±561 * 
Poly(I:C)-HMW 1.00±0.53 vs. 1.30±0.89 1.00±0.56 vs. 1.78±1.40 160±60 vs. 172±187 
Poly(I:C)-LMW 1.00±0.17 vs. 0.71±0.44 1.00±0.49 vs. 0.95±0.68 148±30 vs. 561±411 * 
LPS-EK 1.00±0.34 vs. 8.72±7.34 * 1.00±0.62 vs. 6.09±2.63 * 132±54 vs. 416±621 
ST-FLA 1.00±0.21 vs. 8.84±14.03 1.00±0.71 vs. 0.49±0.67 317±351 vs. 487±663 
FSL-1 1.00±0.11 vs. 3.39±4.21 1.00±0.94 vs. 1.77±1.24 137±58 vs. 117±21 
Imiquimod 1.00±0.49 vs. 1.15±0.66  254±276 vs. 139±57 
SSRNA40 1.00±0.28 vs. 0.80±0.52 1.00±0.47 vs. 0.77±0.30 200±90 vs. 447±479 
ODN2006/1826 1.00±0.09 vs. 1.46±0.98 1.00±0.54 vs. 1.14±0.87 189±86 vs. 2097±1564 * 
Table. 3-2 Influences of TLR agonists on TXB2 secretion 
Data are expressed as mean ± SD, before vs. after stimulation. Two-tailed t-test, *p 
< 0.05, comparing between values before and after stimulation. 
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3.4  TLR agonists decreased TXB2 secretion in mouse HSCs and had no 
effects in SECs 
The same concentrations of TLR-1 to -9 agonists treating primary KCs were also 
tested in mouse SECs and HSCs. TLR agonists had no effects on TXB2 secretion 
in SECs (Fig. 3-11). Interestingly, an overall downward tendency was observed in 
HSCs after TLR agonist stimulation. Furthermore, significant reduction of TXB2 was 
found by applying TLR-3, -5 and -9 agonists (Fig. 3-12). Complete data are shown 
in Table. 3-3. 
 
TLR agonists 
Mouse SECs 
(increased fold) 
Mouse HSCs 
(increased fold) 
Control 1.00±0.87 vs. 0.87±0.69 1.00±0.89 vs. 0.66±0.71 
Pam3CSK4 1.00±0.47 vs. 1.52±0.86 1.00±0.59 vs. 0.42±0.27 
HKLM 1.00±1.24 vs. 1.36±1.39 1.00±0.86 vs. 0.44±0.45 * 
Poly(I:C)-HMW 1.00±0.28 vs. 1.85±1.91 1.00±0.11 vs. 0.38±0.12 * 
Poly(I:C)-LMW 1.00±0.39 vs. 1.28±0.62 1.00±0.14 vs. 0.34±0.05 * 
LPS-EK 1.00±0.47 vs. 1.31±0.65 1.00±0.99 vs. 0.38±0.27 
ST-FLA 1.00±0.44 vs. 1.12±0.51 1.00±0.34 vs. 0.24±0.11 * 
FSL-1 1.00±0.24 vs. 1.24±0.82 1.00±1.53 vs. 0.22±0.32 
SSRNA40 1.00±0.65 vs. 0.84±0.54 1.00±1.50 vs. 0.32±0.40 
ODN1826 1.00±1.18 vs. 1.12±0.71 1.00±0.41 vs. 0.52±0.29 * 
Table. 3-3 Influences of TLR agonists on mouse HSC and SEC 
Data are expressed as mean ± SD, before vs. after stimulation. Two-tailed t-test, *p 
< 0.05, comparing between values before and after stimulation. 
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Fig.3-11 TLR agonists showed no effects in mouse SECs 
Among all TLR-1 to -9 agonists, none of TLR agonists significantly increased TXB2 
secretion in SECs. Data are expressed as mean ± SD, n=6 in each group.  
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Fig.3-12 TLR-3, -5, -6 and -9 agonists decreased TXB2  
secretion in mouse HSCs 
An overall downward tendency was observed in HSCs after TLR agonist stimulation. 
Furthermore, Poly(I:C)-HMW (10ng/ml, 24 h), Poly(I:C)-LMW (10ng/ml, 24 h), ST-
FLA (10ng/ml, 24 h) and ODN1826 (10ng/ml, 24 h) induced significant effects. Data 
are expressed as mean ± SD, two-tailed t-test, *p < 0.05 comparing between values 
before and after stimulation, n=6 in each group.  
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3.5 Specific TLR-1, -2 or -4 antagonists reduced the TXB2 increase caused by 
related TLR agonists 
According to the results above, TLR-1, -2 and -4 seemed to be most possibly related 
to bacterial-induced TXB2 increase. Before treating the HKCs with TLR antagonists, 
the gradient concentration experiments to select the effective concentration of these 
antagonists were tested in TMCs and MKCs (LPS failed to increase TXB2 in TMCs, 
so TLR-4 antagonist was tedted in MKCs). 10µM CU-CPT22, 1µg/ml Mab-mTLR2 
and higher concentrations of these drugs adding in TMCs significantly attenuated 
the increase of TXB2 caused by Pam3CSK4 or HKLM (Fig. 3-13 A, B). 1 µM TAK242 
or higher concentrations in MKCs also had significant effects in reducing LPS-
induced TXB2 secretion (Fig. 3-13 C).  
In order to minimize the adverse effects of TLR antagonists on cells, we chose to 
treat cells with their lowest effective dose. 10µM CU-CPT22, 1µg/ml Mab-mTLR2 
and 1 µM TAK242 were selected in the following experiments. The effects of the 
selected concentrations of TLR antagonists were identified in human and mouse 
KCs. 1 h pretreatment with CU-CPT22 (10µM), Mab-mTLR2 (1µg/ml) or TAK242 
(1µM) in human Kupffer cells and mouse Kupffer cells siginificantly reduced the 
TXB2 increase caused by Pam3CSK4, HKLM or LPS-EK (Fig. 3-13 D,E) 
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Fig.3-13 Concentration gradient experiments of TLR-1/-2/-4 antagonists 
A-C: Different concentrations of CU-CPT22, MAb-mTLR2 or TAK242 were added 1 
h before stimulation of TLR-1, -2 or -4 agonists. Pretreatment with 10µM CU-CPT22, 
1µg/ml MAb-mTLR2, 1µM TAK242 and higher concentrations of these 3 drugs 
significantly attenuated the increase of TXB2 by Pam3CSK4, HKLM or LPS-EK.  
Mean values of control group after stimulation used as positive control. 1 h 
pretreatment with CU-CPT22 (10µM), Mab-mTLR2 (1µg/ml) or TAK242 (1µM) in 
human Kupffer cells (D) and mouse Kupffer cells (E) reduced TXB2 increase caused 
by Pam3CSK4 (0.1 µg/ml, 24 h), HKLM (10e8 cells/ml, 24 h) or LPS-EK (10ng/ml, 
24 h). Data are expressed as mean ± SD, control after stimulation used as positive 
control in human KCs. Two-tailed t-test, *p < 0.05, n=6 in each group.  
LMU doctoral thesis                                                   Jiang Zhang  
53 
 
3.6 Effects of TLR-1, -2 and -4 antagonists on bacterial-induced TXB2 increase  
Antagonists of TLR-1, -2 and -4 were additionally added to human KCs to 
investigate potential treatment options to reduce the bacterial-induced TXB2 
secretion. TXB2 increase caused by Gram (-) bacterial products were attenuated by 
1 h pretreatment with TLR-1, -2 or -4 antagonists before stimulation (Fig. 3-14 A-C). 
CU-CPT22 and Mab-mTLR2 also had effects on TXB2 secretion following Gram (+) 
bacterial stimulation (Fig. 3-14 D-F). Only Mab-mTLR2 significantly decreased C. 
albicans-induced TXB2 secretion (Fig. 3-14 G).  
Microbial 
isolates 
Control 
(%positive control) 
CU-CPT22 
(%positive control) 
Mab-mTLR2 
(%positive control) 
TAK242 
(%positive control) 
K. pneumoniae 
7.64±8.13 vs. 
100.00±8.22 
6.72±7.77 vs. 
44.04±19.20 * 
8.04±8.53 vs.  
64.53±16.50 * 
6.87±7.28 vs. 
34.15±14.05 * 
E. coli 
15.48±13.64 vs. 
100.00±24.79   
13.02±10.76 vs. 
23.20±12.22 * 
15.25±12.68 vs. 
35.16±18.15 * 
15.33±15.01 vs. 
50.07±39.66 * 
E. cloacae 
6.16±7.13% vs. 
100.00±38.02 
5.75±6.18 vs. 
30.24±22.65 * 
5.67±6.17 vs.  
27.00±21.21 * 
4.18±4.46 vs. 
41.48±38.36 * 
E. faecium 
13.95±8.84 vs. 
100.00±26.56 
8.75±4.71 vs. 
25.34±26.38 * 
10.96±6.03 vs.  
15.81±3.50 * 
11.96±5.03 vs. 
53.10±45.87 
S. pneumoniae 
25.97±29.51 vs. 
100.00±26.66 
6.19±6.38 vs. 
37.23±25.18 * 
9.96±10.57 vs.  
16.35±13.66 * 
28.13±37.54 vs. 
52.42±41.85 
S. aureus 
2.59±0.61 vs. 
100.00±45.45   
4.17±1.07 vs.  
27.95±8.12 * 
4.72±4.45 vs.  
25.90±6.38 * 
6.47±5.79 vs. 
61.16±42.37 
C. albicans 
8.94±2.17 vs. 
100.00±33.23 
11.57±5.30 vs. 
80.16±15.63 
16.83±10.69 vs.   
45.00±29.99 * 
7.66±1.34 vs. 
74.14±32.76 
Table. 3-4 Influences of TLR-1, -2 and -4 antagonists on bacterial-induced 
TXB2 increase 
Data are expressed as mean ± SD (mean values of control group after stimulation 
used as positive control), before vs. after stimulation. Two-tailed t-test, *p < 0.05, p 
value was calculated by comparing values after stimulation in each antagonist 
groups with control group.  
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Fig.3-14 Effects of TLR antagonists in different kinds of microbial isolates 
1 h pretreatment with CU-CPT22 (10µM), Mab-mTLR2 (1µg/ml) and TAK242 (1µM) 
in human Kupffer cells respectively attenuated TXB2 increase caused by Gram (-) 
bacteria (A-Klebsiella pneumoniae, B-Escherichia coli and C-Enterobacter cloacae, 
8µg/ml 24 h stimulation). Cu-CPT22 and Mab-mTLR2 also decreased TXB2 
induced by Gram (+) bacteria (D-Enterococcus faecium, E-Streptococcus 
pneumoniae and F-Staphylococcus aureus, 8µg/ml 24 h stimulation). Only Mab-
mTLR2 had effects on fungus-induced TXB2 increase (G-Candida albicans, 8µg/ml 
24 h stimulation). Mean values of control group after stimulation used as positive 
control. *p < 0.05 compared to the positive control, n=4 in each group. 
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3.7 Effects of combined TLR antagonists on bacterial-induced TXB2 increase  
The effects of combined TLR antagonists were also compared with each single drug. 
Either single TLR-1, -2 and -4 antagonists or combined drugs (mix group, including 
Mab-mTLR2, CU-CPT22 and TAK242, 1 h pretreatment before stimulation) 
significantly decreased TXB2 increase by Gram (-) bacterial stimulation (K. 
pneumoniae, E. coli and E. cloacae, 8µg/ml, 24 h stimulation), In addition, combined 
substance achieved a better effect than any single substances. Details are shown 
in Table. 3-5. 
 
Microbial 
isolates 
Control 
(Positive %) 
CU-CPT22 
(Positive %) 
Mab-mTLR2 
(Positive %) 
TAK242 
(Positive %) 
Mix 
(Positive %) 
K. pneumoniae 100.00±24.28 50.37±17.38 *#  36.25±18.87 *# 42.18±22.55 *# 15.62±10.32 * 
E. coli 100.00±12.18 39.31±13.33 *# 64.83±17.14 *# 53.19±14.12 *# 20.84±4.48 * 
E. cloacae 100.00±17.97 37.61±19.88 *# 43.38±13.46 *# 34.89±11.52 *# 14.97±2.70 * 
 
Table. 3-5 Comparision between combination and single usages of  
TLR-1, -2 and -4 antagonists  
 
Data are expressed as mean ± SD, the control group used as a positive control. P 
values were calculated by comparing values after stimulation in each antagonist 
groups with control group (*p < 0.05) or Mix group (#p < 0.05), two-tailed t-test.   
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Fig.3-15 Combined use of TLR-1, -2 and -4 antagonists achieved a better 
effect on decreasing Gram-negative bacterial induced TXB2 increase 
1 h pretreatment in human KCs with CU-CPT22 (10µM), Mab-mTLR2 (1µg/ml), 
TAK242 (1µM) or mix drugs (combined use of these three substances) reduced 
TXB2 increase following Gram-negative bacterial stimulations (A-K. pneumoniae, 
B-E. coli and C-E. cloacae, 8µg/ml 24 h stimulation). Effects of the combination 
were better than individual TLR-1, -2 or -4 antagonists. Data are expressed as 
mean ± SD, the control group used as a positive control. Two-tailed t-test, *p < 0.05 
comparing with positive control, #p < 0.05 comparing with mix group, n=6 in each 
group. 
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4. Discussion 
This study investigated the function of TLRs in bacterial-induced TXA2 increase in 
nonparenchymal liver cells. Novel findings in our research were the following: (1) 
Gram-positive, Gram-negative and fungal microbial isolates extracted from SBP 
patients increased TXB2 secretion in HKCs, MKCs and TMCs; (2) SECs and HSCs 
did not secrete TXB2 by TLR activation, while KCs did. Only TLR-1/2, -2 and -4 
agonists increased TXB2 secretion in HKCs and MKCs among all TLR agonists; 
and (3) TLR-2 antagonist showed the most effective effect in reducing bacterial-
induced TXA2 secretion in comparison with TLR-1 and -4 antagonists. Combination 
of these 3 agents even attained a better effect. These results were achieved by 
using primary KCs from human and mouse, primary SECs and HSCs from mice 
and THP-1 cell line. 
4.1 Responses to microbial isolates in different kinds of macrophages 
The initial set of experiments showed the effective microbial isolates and TLR 
agonists increasing TXB2 secretion after 24 h stimulation. 7 most common isolates 
extracted from SBP patients all increased TXB2 secretion in 3 kinds of macrophages. 
Macrophages derived from humans (HKCs and TMCs) seemed to be more 
sensitive to Gram (-) bacterial isolates while Gram (+) bacterial isolates induced 
more TXB2 in MKCs (Fig. 3-4, 3-5, 3-6). This discrepancy may implied the difference 
between human and mouse in immune function about bacterial defense. Previous 
LMU doctoral thesis                                                   Jiang Zhang  
58 
 
publications demonstrated differences between human and mouse immunology: 
the TLR-2 expression on mouse peripheral blood leukocytes was much lower than 
on human [78, 79]; macrophages from mice lacked CD4 while CD4 exited on 
human macrophages [80] ; expression of the IgG Fc receptor (FcγR) system also 
differed between mouse and human [81, 82]. However, researches spurred in 
differences between mouse and human on functions of TLRs in present study are 
still young, our results suggest more attention in this field in further investigations. 
4.2 Responses to TLR agonists in different kinds of macrophages 
Special TLR-1 to -9 agonists were then tested in different kinds of macrophages to 
find the responsible TLRs increasing TXB2. Only Pam3CSK4, HKLM and LPS had 
significant effects in both HKCs and MKCs, Pam3CSK4 and HKLM also worked on 
TMCs (Fig. 3-7, 3-8, 3-9). These common effects implied TLR-1, -2 and -4 were 
most possibly related to the bacterial-induced TXB2 increase.  
Previous publications found the expression of TLR-4 on undifferentiated THP-1 
cells was lower than primary human monocytes and differentiated THP-1 cells were 
even unable to see reliable TLR-4 expression on the surface [83]. Our results also 
confirmed that conclusion since only TMCs failed to increase TXB2 by LPS 
stimulation. Both Poly(I:C)-LMW and ODN2006 had significant effects on TMCs, 
however, ODN2006 caused the most significant TXB2 secretion while Poly(I:C)-
LMW induced the least among all effective TLR agonists (Fig. 3-9). It has reported 
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earlier that Poly(I:C) is a potent adjuvant, acting through the TLR-9/MyD88-
dependent pathway [84, 85]. We doubted that the TXB2 increase caused by TLR-3 
agonist was due to its adjuvant effect with TLR-9 pathway, and the effect may only 
exited on Poly(I:C)-LMW. In humans, TLR-9 is expressed primarily by plasmacytoid 
dendritic cells and B cells rather than macrophages [86, 87]. THP-1 cells can be 
differentiated to both dendritic cells and macrophages, which may be the reason 
why TLR-9 agonist only worked on TMCs.   
TLR-2 has a unique ability to heterodimerize with TLR-1 and -6. In unstimulated 
KCs, the mRNA expression for TLR-1, TLR-2, and TLR-6 was approximately 
10:40:1 [88, 89]. That may explain why both TLR-1/2 and TLR-2 agonists increased 
TXB2 secretion while TLR-6/2 agonist failed. Another possible explanation may be 
that FSL-1 is a kind of pure diacylated lipoproteins needing the direct association 
of TLR-6/2 and CD36, whereas, TLR-1/2 heterodimers are formed in response to 
Pam3CSK4 (one kind of triacylated lipoproteins) in absence of CD36 [34]. CD36 is 
expressed on KCs but the basal expression is low [90, 91], we therefore suspected 
the process by which KCs recognize dimeric antigens requires the assistance of 
other cells containing CD36.  
Numerous antagonists targeting TLRs including antibodies, oligonucleotides and 
small molecular inhibitors are currently under preclinical studies, clinical trials, in 
vitro and in vivo experiments [45, 47, 92]. The discrepancy of TLR function among 
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HKCs, MKCs and TMCs may also lay basis for translating results from animal 
experiments and cell lines to the human situation in future investigations. 
4.3 Responses to TLR agonists in different nonparenchymal liver cells 
Prostaglandin (PG) and TXA2 produced by NPCs in liver played important roles in 
increasing portal pressure after TLR activation [14, 32, 93, 94]. Yet, only a few 
publications reported the functions of TLRs in different NPCs. Our study was the 
first to investigate the differences among mouse KCs, SECs and HSCs after TLR 
agonist stimulation. TLR agonists induced no significant TXB2 increase in SECs 
despite their 70% amount in NPCs. This result was in line with previous publication 
that anaphylatoxin C5a significantly increased the release of TXA2 and PG in both 
KCs and HSCs, but not in SECs [95-97]. Compared with SECs and HSCs, KCs 
possessed the largest amount of Gs-linked prostaglandin E2 receptor (GPER). 
However, the functional evidence for this receptor has not proved so far [93]. We 
speculated that the strong expression of GPER in KCs may be responsible for the 
increased TXB2 after stimulation of TLR agonists. 
HSC can present bacterial antigens to natural killer T cells and suppress 
proliferation of T cells [98-100]. Activated HSCs can also simultaneously inhibit its 
activation through a negative feedback loop via IL-10 [101, 102]. Thus, HSCs could 
limit bacterial infection and are critical in liver’s immune tolerance. These 
immunosuppressive characteristics may also explain why TLR agonists decreased 
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TXB2 secretion in HSCs. Myofibroblast-like cells are usually transdifferentiated from 
activated HSCs, which are often triggered by infections or hepatotoxic drugs. 
Transdifferentiation accompanied by a change in receptor expression such as G-
protein coupled receptors for PGF2α and TXA2 [103, 104]. This apparent 
discrepancy is also related to vitamin A droplets loss and augmented contractile 
activity [105-107]. Most TLR 1-9 agonists are products or components of bacteria, 
and may differentiate HSCs with an apparent and functional change. This 
differentiaction may also explain the oppsite effects of TLR agonists and 
anaphylatoxin C5a in HSCs.    
4.4 Clinical applications 
TLR-1, -2 or -4 antagonists were additionally added in HKCs. The number of 
effective antagonists was consistent with the levels of TXB2 secretion caused by 
different microbial isolates: Gram (-) bacteria induced the most relevant TXB2 
secretion in HKCs, the increase was reduced by all 3 kinds of antagonists; TLR-1 
and -2 antagonist attenuated TXB2 secretion following Gram (+) bacterial 
stimulations; in comparison, only Mab-mTLR2 reduced C.albicans-induced TXB2 
increase (Fig. 3-14). Mab-MTLR2 had significant effects on all 7 kinds of microbial 
isolates, supporting TLR-2 may recognize the most diverse set of PAMPs including 
lipoarabinomanan, peptidoglycan, lipoteichoic acid from Gram (+) and Gram (-) 
bacteria [108-110] as well as fungi [111, 112]. TLR-2 expression in monocytes were 
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significantly overexpressed in patients with tuberculosis [44], systemic lupus 
erythematosus [45] and myelodysplastic syndromes [46]. TLR-2 polymorphisms 
were also related to increased susceptibility toward SBP in cirrhotic patients with 
ascites [24]. Despite a rare condition, positive fungal cultures were found to be 
associated with a significantly higher mortality than patients with SBP alone [16, 17, 
113]. Lack of specific indicators and low culture success rate often lead to delayed 
diagnosis and treatment of concomitant fungal infection in SBP patients. The effects 
of TLR-2 antagonist in our experiments suggested TLR-2 as a potential marker for 
SBP patients accompanied with fungal infections. 
Resistant organisms are becoming an emerging problem due to the wide-spread 
use of oral antibiotics in SBP patients [18, 24, 114]. Antibodies targeting TLRs may 
represent an attractive therapeutic option. OPN-305, the first humanized IgG4 
monoclonal antibody against TLR-2 on monocytes, was tested in a randomized, 
double-blind, in-human phase I study. A single infusion of OPN-305 provided 80% 
inhibition of interleukin 6 release for at least 14 days, with no significant adverse 
findings. This study proved the safety and tolerability of OPN-305, providing further 
evidence of application of TLR2 antagonists in infections [115]. Sepsis associated 
death can be decreased by anti-TLR-2 or anti-TLR-4 antibody alone [116]. The 
synergistic effect of TLR-1, -2 and -4 antagonists in our experiments (Fig. 3-15) also 
support the combined application in patients with complicate and severe infections.  
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4.5 Conclusions 
These are the first experiments to treat human primary KCs with different, clinically 
relevant microbial isolates. TLR-1, -2 and -4 play vital roles in bacterial-induced 
TXB2 secretion. TXA2 has been shown to be an important intrahepatic 
vasoconstrictor which increases the portal pressure and participate in the 
progression of ACLF. In the present study we identified TLR-2 as novel and 
important target in the pathway of TXB2 production by human Kupffer cells. Different 
microbial isolates induced KCs to secrete TXA2 and inflammatory factors using the 
same route: activation of MAPK-associated pathway by TLR-2 leading to factor 
secretion. Therefore, inhibition of TLR-2 might be a potential marker and an 
attractive treatment option for liver cirrhosis and infections. Hereby the dynamic and 
in particular TXB2-dependent component of portal pressure increase might be 
attenuated with great benefit for these patients.  
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